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The current COVID-19 pandemic has challenged health systems and communities globally. As 
such, several countries have embarked on national COVID-19 vaccination programmes in order 
to curb spread of the disease. However, at present, there isn’t yet enough dosages to enable 
vaccination of the general population. Different vaccine prioritization strategies are thus being 
implemented in different communities in order to permit for a systematic vaccination of indi-
viduals. Here, on behalf of the World Heart Federation, we emphasize the need for individuals 
with Cardiovascular disease to be prioritized in national vaccine prioritization programmes as 
these are high risk individuals.
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Summary of COVID-19 vaccine landscape
Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2) has caused more than 2.5 million deaths worldwide within the first year of the pandemic [1]. 
SARS-CoV-2 is a single stranded, positive-sense, RNA virus that encodes many open reading frames (ORFs) 
[2]. The viral ORFs are responsible for the synthesis of several accessory and structural proteins such as 
the transmembrane spike (S) glycoprotein and the replicase enzyme. Recognition and attachment of the 
S protein to human epithelial cells lined with ACE2 receptors are important events in the hallmark of 
COVID-19 pathophysiology. As such, the S protein has become a leading target in the development of 
novel vaccines and neutralising antibodies against SARS-CoV-2. The urgent development of COVID-19 
vaccines has been accelerated by the increased demands for intensive care facilities and exhaustion of 
the medical facilities as well as the economic consequences of successive lockdowns that most countries, 
in different forms, have followed. Vaccines possess great potential in mitigating COVID-19 as findings 
suggest that the action of neutralizing antibodies is crucial for viral clearance [3].
Various approaches are under investigation to develop an effective and safe COVID-19 vaccine. Tremendous 
efforts from the scientific community, governments, and private sector have to date resulted in hundreds of 
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vaccine-related projects aimed at mitigating the spread of the deadly virus (https://covid19.trackvaccines.
org). At present, over 80 vaccine candidates are undergoing clinical testing in more than 220 clinical trials 
(Figure 1). Several approaches are being utilized in the development of efficacious COVID-19 vaccines to 
elicit an immune response upon exposure to non-virulent forms of the viral antigens, preventing future 
infection from the virus. Potential COVID-19 vaccines currently under development can be classified into 
the following categories: live/attenuated, inactivated, protein subunit, nucleic acid-based (mRNA or DNA-
based) and vector-based (Table 1). With such diversity in the vaccine design approaches, it is not surprising 
that distinct population groups may respond differently to the various vaccine types. Therefore, the merits 
and demerits of each vaccine type relative to target recipient groups is an important consideration for vac-
cination programs. Much as some strategies possess great promise, there are also challenges associated with 
Figure 1: Landscape of COVID-19 vaccines. (A) Several vaccines are in the production pipeline at sev-
eral development stages. (B) Although different approaches are being employed in the development of 
COVID-19 vaccines, many of the vaccines currently undergoing clinical trials are subunit and vector-based 
vaccines. (C) The global distribution of COVID-19 vaccine recipients as at 22 February 2021. Data source: 
Covid-19 Vaccine Tracker Updates: The Latest – The New York Times (nytimes.com); COVID19 Vaccine 
Tracker (trackvaccines.org); https://ourworldindata.org/covid-vaccinations.
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other vaccine design approaches. For instance, whereas protein subunit vaccines, coupled with adjuvants, 
are generally thought to induce a robust immune response [4], they require longer production time which 
demand complex downstream purification steps. In the case of a pandemic where emergency medical inter-
ventions are required as a matter of urgency, this approach may be less suitable. On the other hand, mRNA 
vaccines are much faster and relatively easier to produce, although their ultra-low temperature storage 
requirement is less convenient in low resource settings (Table 1). It is however important to have a variety 
of vaccine types as we are already seeing in many countries since this will allow the vaccines to complement 
each other in developing herd immunity globally.
Other less common technological approaches such as the use of probiotics, heat-inactivated plasma and 
dendritic cells are also being explored in COVID-19 vaccine development [5]. The orally administered pro-
biotic, Bifidobacterium, is currently undergoing Phase I clinical trials [6]. Trials are also being conducted 
on dendritic cells that are engineered to express the SARS-CoV-2 antigen [7], thus initiating an immune 
response. Interestingly, it seems the majority of COVID-19 vaccine candidates presently undergoing clinical 
trials are S protein subunit-based vaccines (Figure 1; Table 2). Subunit vaccines coupled with adjuvants are 
generally known to elicit a robust immune response in several disease models [8]. The emerging increase 
in SARS-CoV-2 mutations is a key concern which arises from the sole reliance on S proteinbased vaccines. 
SARS-CoV-2 variants in South Africa, the United Kingdom (UK) and Brazil have recently been described [9]. 
The South African 501Y.V2 variant is characterised by three mutations; K417N (a lysine to asparagine substi-
tution at amino acid position 417 in the S protein), E484K (a glutamic acid to lysine substitution at amino 
acid position 484 in the S protein) and N501Y (an asparagine to tyrosine substitution at amino acid position 
501) which all occur in the S protein [10]. However, the effect of these mutations on S protein-based vaccines 
is yet to be fully determined. Live attenuated and inactivated vaccines composed of multiple antigens may 
therefore be more efficient options as they can elicit an immune response not only directed towards the S 
protein. Nonetheless, long-term immunity and safety of inactivated vaccines requires further confirmation 
as previous studies with inactivated SARS-CoV vaccines have resulted in lung eosinophilia [11].
Table 1: COVID-19 vaccine types, mechanisms, and features.
Vaccine type Mechanism of action Advantages Disadvantages
Live attenu-
ated 
Produce by growing the virus 
in unfavourable conditions 
or by generating a geneti-
cally weakened version of the 
virus.
(1) Relatively higher efficacy 
than inactivated vaccines.
(2) Immune response is 
directed against many SARS-
CoV-2 antigens.
(1) Production and handling are 
associated with major biosafety 
risks. 
(2) May be unsuitable for use in 
some age groups. 
Inactivated SARS-CoV-2 is inactivated by 
exploiting different chemi-
cal techniques to produce a 
vaccine. 
(1) More stable than live 
attenuated vaccines.
(2) Immune response is 
directed against many SARS-
CoV-2 antigens. 
(1) Short duration of immune 
memory which demands inocula-
tion of higher vaccine doses.
(2) May result in hypersensitivity.
Subunit The S protein or its fragments 
are produced by rDNA tech-
nology to make a vaccine. 
(1) Elicit robust immune 
response, when combined 
with adjuvants.
(1) Require stringent downstream 
purification steps which are often 
expensive.
DNA-based DNA plasmids are used to 
induce cells to produce the 
S protein, thus activating an 
immune response. 
(1) Great flexibility for 
manipulation of the coded 
antigen. 
(2) Quick to produce. 
(3) High antibody titres.
(1) Specialized and complex delivery 
(electroporation). 
(2) Repeated doses may cause toxicity.
(3) Relatively lower immune 
responses.
mRNA mRNA vaccines temporarily 
induce cells to produce the 
antigen protein encoded.
(1) Low production costs.
(2) Quick to produce. 
(1) Vaccine preparations must be 
kept at ultralow temperatures.
Vector DNA coding for the S protein 
is conveyed into cells by viral 
vectors. By inserting the DNA 
in a virus, it is possible to 
exploit the virus’s great abil-
ity to infect and deliver the 
mRNA into the human cells.
(1) Candidate vaccines may 
induce a mucosal immunity 
capable of neutralizing the 
virus, thus inhibiting its abil-
ity to enter the human body.
(1) Possibility of presenting varied 
immune responses.
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At the time of this article submission, more than 15 vaccines have been approved for emergency use in 
different countries (https://covid19.trackvaccines.org) and this is changing rapidly (Table 2). Notably, many 
of the currently approved vaccines are vector-based and inactivated vaccines (Table 2). Most recombinant 
COVID-19 viral vector vaccines act as immunogens that are engineered to facilitate the expression of a variety 
of antigens. It is however worth noting that two mRNA vaccines, from Pfizer and Moderna, have been already 
approved in many countries and are thus being used for most vaccination programs globally (Figure 1). These 
vaccines are characterised by the mRNA sequence of the S protein, carried by lipid microvesicles (liposomes). 
A key advantage of mRNA-based vaccines is that they facilitate the transient expression of antigenic peptides 
thus evoking robust major histocompatibility complex-I (MHC-I) presentation and cytotoxic T lymphocytes 
(CTL) responses. Data from clinical trials on both vaccine regimens revealed that the safety was overall reas-
suring as no unexpected patterns of concern were identified [12]. Reported side effects upon vaccination 
ranged from fatigue, myalgia, arthralgia, and headache [13]. Both vaccines have been shown to possess over 
94% efficacy (Table 2) and have thus been opted into many COVID-19 vaccination programs worldwide.
Table 2: List of all 12 vaccines currently approved by at least one country (Date: 28 February 2021).
Developer Name Type Countries 
in use
Immunogenic features Efficacy 
FBRI/Novavax EpiVacCorona Protein 01 High levels of S-specific neutral-
izing antibodies.
Not available
Pfizer/BioNTech BNT162b2 mRNA 65 2 repeated doses (28 days apart) 
which induce elevated concentra-
tions of neutralizing antibody 
titers. Also induce CD4+ and 
CD8+ T cells responses.
95%
Moderna mRNA-1273 mRNA 40 2 repeated doses (28 days apart) 
which induce neutralizing anti-
bodies and CD4+ and CD8+ T cell 
responses.
94.1%
Janssen (Johnson & 
Johnson)
Ad26.COV2.S Vector 1 Single dose vaccine inducing 
neutralizing antibodies.
85%
CanSino Ad5-nCoV Vector 3 Strong immune response with 
single delivery but impeded due 
to pre-existing immunity.
65.7%
Gamaleya Sputnik V Vector 38 Induces high neutralizing anti-
body titers. Also induces CD4+ 
and CD8+ T cells responses. 
91.4%
Oxford/Astra Zeneca AZD1222 Vector 56 Strong immune response and 
high neutralizing antibodies with 
single injection (Low pre-existing 
immunity).
62%
Serum Institute of 
India
Covishield Vector 13 Oxford-AstraZeneca vaccine is 
being manufactured locally by the 




Bharat Biotech Covaxin Inactivated 2 N/A 81%
Sinopharm (Wuhan) Vero Cells Inactivated 2 Enhanced induction of neutral-
izing antibodies and enhanced 
immunogenicity.
79%
Sinovac CoronaVac Inactivated 12 Elevated induction of neutralizing 
antibodies and enhanced immu-
nogenicity.
50-91%*
Sinopharm (Beijing) BBIBP-CorV Inactivated 16 Safe and high antibody titers. 79-86%*
* variations in results obtained in different trials.
Data retrieved from the COVID19 vaccine tracker of scientists of McGill University, Canada, accessed on 28 February 2021 
(https://covid19.trackvaccines.org/vaccines).
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Importance of COVID-19 vaccine for people with cardiovascular disease
Numerous studies have looked at the association of cardiovascular disease (CVD) and its risk factors with 
COVID-19 severity. For example in a Chinese study, the COVID-19 mortality rate was 2.3% in individuals 
without any pre-existing medical conditions, and was elevated to 6.0% for patients with hypertension, 7.3% 
for patients with diabetes, and 10.5% for patience with CVD [14]. Other studies have showed that both the 
susceptibility and outcomes of COVID-19 strongly correlate with CVD [15–18]. Indeed, evidence from several 
cohort studies has indicated that CVD accounts for approximately between 15–36% of total COVID-19 mor-
talities (Figure 2) [19–20]. Studies have shown that CVD patients present a threefold risk for progression 
towards serious disease, as evidence by the higher number of patients either requiring mechanical ventila-
tion (22% vs. 8%), ICU (intensive care unit) (13% vs. 4%) admission or dying (17% vs. 5%) [19]. In addition, 
CVD patients develop complications such as acute respiratory distress syndrome, malignant arrhythmias, 
and acute kidney injury in the course of disease [19]. Results from a multicentre cohort study of 191 patients 
with COVID-19, also indicated that out of 33 patients with acute cardiac injury, 32 died [20].  CVD is thus 
an important COVID-19 risk factor requiring for early intervention and mitigation and therefore individuals 
with CVD should be prioritized as a high risk group for vaccination. This is particularly crucial because more 
than 400 million individuals across the globe have CVD [21]. However, the disproportionate burden of CVD 
in low- and middle-income countries, where vaccine dissemination is still limited is worrisome.
Although, SARS-CoV-2 generally results in mild disease in approximately 80% of the cases, some indi-
viduals progress to a severe respiratory illness characterized by hyperinflammatory syndrome, multiorgan 
dysfunction, and death [22]. There are several mechanisms via which individuals with CVD and hypertension 
present a greater risk of severe COVID-19 clinical presentation or mortality (Figure 3). The first mechanism 
involves a dysregulation of ACE2 receptors in vascular endothelial cells of CVD patients [22–23]. Following 
initial recognition of ACE2 receptors by the S protein, the metallopeptidase domain protein (ADAM17) 
expression is upregulated to facilitate cleavage of ACE2 from the cell membrane [24]. This results in a loss 
of ACE2-mediated protection against the effects of the renin angiotensin aldosterone system (RAAS) which 
Figure 2: Distribution of CVD risk factors in COVID-19 mortality. (A) CVD and hypertension are 
responsible for most of COVID-19 related mortalities. (B) Hypertension is a major contributor to COVID-
19 mortality. Data sourced from study by Li et al., 2020 [19].
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in turn promotes vascular contraction and endothelial injury. In addition, epithelial injury also causes an 
up-regulation of tissue factor expression and imbalance of fibrinolysis system [25]. Evidence from previous 
studies has indeed shown that ACE2 expression on the cell surface is reduced after SARS-CoV-2 infection 
[26]. ACE2 reduction induces an exaggerated release of several pro-inflammatory cytokines into the circula-
tion, thus inducing a cytokine storm [27]. Together these events may trigger critical illness and inflamma-
tion which may further aggravate pre-existing cardiovascular disorders including heart failure, ischemia, 
and arrhythmias [23]. Notably, an upsurge in inflammatory biomarkers in COVID-19 patients with CVD has 
been reported, indicating that inflammatory cell necrosis promoted inflammatory response leading to myo-
cardial damage, or fulminant myocarditis [28–29]. In this manner, CVD may worsen outcomes in COVID-19 
patients. 
CVD may also result in further complications in COVID-19 patients due to the association of chronic CVD 
with a myriad of other risk factors such as obesity and diabetes which are additional COVID-19 risk factors. In 
fact, the American Heart Association reports that approximately 68% of people with diabetes (who are over 
65 years) die from heart disease. A combination of CVD and diabetes therefore puts individuals at further 
risk of COVID-19 related mortality. Furthermore, CVD and diabetes may result in immune dysregulation 
which predisposes individuals at risk of a more severe COVID-19 clinical manifestation [30]. Evidence from 
previous work has highlighted a relationship between CVD and immune dysregulation [31–32] and this 
association may trigger worse outcomes in COVID-19 patients. It is also worth noting that CVD are linked 
to chronic activation of inflammatory pathways. Therefore, it can also be speculated that since SARS-CoV-2 
infection generally elicits an inflammatory response, a synergistic inflammatory cascade may possibly be 
triggered in CVD patients, resulting in COVID-19 related complications and multi organ failure.
It is thought that SARS-CoV-2 can directly replicate inside the myocardium resulting in primary myocar-
dial injury which may further aggravate pre-existing myocardial injury [33–34]. It is unknown if the effects 
of direct viral replication in the heart may be amplified in patients with chronic CVD, especially in those 
with coronary artery disease. From previous evidence, viral infection was shown to cause endothelial dys-
function leading to accelerated atherogenesis and induction of coronary plaque instability [35–36]. These 
cardiac complications thus present a greater risk of mortality in CVD patients. It is also plausible that CVD 
patients are at high risk from SARS-CoV-2 infection due to their limited physiological and haemodynamic 
reserve under oxidative stress. Heart failure patients generally have reduced cardiac output, which is further 
Figure 3: Outcomes of COVID-19 infection in CVD patients.
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burdened by reduced pulmonary function during COVID-19. This increased pressure may further stress CVD 
patients resulting in adverse events from COVID-19. Increased oxidative stress and elevated blood pressure 
can in turn damage vascular endothelium causing hypercoagulability in COVID-19 patients with CVD [37].
Recent reports also indicate that COVID-19 patients with CVD frequently developed complications 
including acute liver injury and acute renal injury during hospitalization [19]. Patients with CVD were also 
reported to exhibit poor compensatory ability of cardiac function and inflammatory cytokine storm, which 
exacerbated microcirculation ischemia and hypoxia of liver cells and further aggravated liver function injury 
[19]. Taken together, these findings suggest that individuals with CVD present a high risk as CVD is usually 
associated with worse COVID-19 outcomes. 
COVID-19 vaccine access – Global equitable and fair distribution
Since late 2020 several regulators have approved different COVID-19 vaccines including the European Med-
icines Agency (EMA), the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Health-
care products Regulatory Agency (MHRA). The three more widely approved vaccines that have so far been 
approved by these stringent authorities are Pfizer/BioNTech, Oxford/AstraZeneca, and Moderna. The World 
Health Organization Strategic Advisory Group of Experts on Immunization (SAGE) has recently issued 
interim recommendations for use of the Oxford/AstraZeneca COVID-19 vaccine [38].
Intense discussions around the world arose on 1) global equitable and fair access and 2) allocation of 
COVID-19 vaccines. South Africa is the first country in Africa that has started a vaccination program on 18th 
February 2021. At the time of this article submission, Israel has by far the most widely vaccinated popula-
tion, with approximately 43 doses per 100 individuals (Figure 1). Although most of the European popula-
tion is undergoing an intensive vaccination program, so far only between 1–11% of the population has been 
vaccinated. In contrast, vaccination in low- and middle-income countries is much slower with most of Africa 
is yet to be vaccinated against COVID-19. Initial vaccination programs are prioritising different populations, 
but in general most strategies include frontline health and social care workers, individuals over 65 years, 
and people with existing chronic conditions who are considered to be at high risk of developing severe 
COVID-19. It is important to emphasize that individuals with CVD should be considered among the latter 
and should be included as a priority in such vaccination programs. 
Back in April 2020, the Access to COVID-19 Tools (ACT) Accelerator was initiated to address those issues. 
ACT Accelerator is a unique global collaboration led by the World Health Organization to support the devel-
opment and equitable distribution of COVID-19 tests, treatments and vaccines. COVID-19 Vaccines Global 
Access (COVAX) is one of three pillars of the ACT Accelerator and offers a global solution to the COVID-19 
pandemic. COVAX is a platform to accelerate the development and manufacture of COVID-19 vaccines, and 
‘to ensure that people in all corners of the world will get access to COVID-19 vaccines once they are available, 
regardless of their wealth [39].’ It is also very important to implement strategies that will allow for massive 
and fast vaccination as soon as vaccines become available. The example of the successful massive vaccina-
tion program in Israel supports this concept. Close to 90% of people aged 60 and older in the country have 
received their first dose of Pfizer/BioNTech two-dose prime-boost vaccine so far. There was a 41% drop in 
confirmed COVID-19 infections in that age group, and a 31% drop in hospitalizations from mid-January to 
early February [40]. In addition, recent data published online showed that vaccination reduced the viral load 
by 1.6x to 20x in individuals who were positive for SARS-CoV-2. This estimate might improve after more 
individuals receive the second dose. The overall direction is clear: COVID-19 vaccination with the Pfizer/
BioNTech vaccine can 1) protect individual from severe COVID-19 disease, and 2) can also reduce transmis-
sion and halt the spread of COVID-19 and potentially end the pandemic [41].
Vaccine Prioritization 
Initial vaccination programs are prioritising different populations, but in general, most include the groups 
identified as Tier 1 by the World Health Organization including frontline health and social care workers, 
people over 65 years, and people under the age of 65 years who have underlying conditions that put them 
at a higher risk of death.
The importance of COVID-19 vaccination for people with cardiovascular disease
Among the latter a very important group is people with CVD, as mentioned this population is at high risk 
for severe disease and should be considered as priority individuals for vaccination. By reducing the likeli-
hood of infection in this population, not only will there be a direct impact and decrease in mortality, but 
also a reduc tion of patients with the need of intensive care facilities including mechanical ventilation. This 
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will help to reduce the current pressure on the healthcare systems, which is one of the main issues many 
countries are facing and directly related with the total number of infected people as well as the number of 
high-risk patients being infected, such as those with CVD. 
The importance of COVID-19 vaccination for healthcare workers
COVID-19 vaccine allocation - often referred to as vaccine prioritization - sparked again highly emotional dis-
cussions when healthcare workers were not considered in the first phase of vaccination campaigns. Vaccine 
rollout plans were developed at national levels on how to distribute COVID-19 vaccines in light of potentially 
limited supply during the early rollout phase. While efforts were often focussing on elderly people and 
people at high risk for severe disease, healthcare workers and other frontline workers at high daily risk of 
exposure to SARS-CoV-2 are not always considered for vaccination during the first phase. As a result, many 
healthcare professionals around the globe raised their voices to be heard [42]. In South Africa, the petition 
‘We need a COVID-19 vaccine plan now!’ called on the Department of Health to start ‘vaccinating frontline 
health workers, followed by those most at risk including elderly people and people with comorbidities,’ a 
motion that was supported by Professor Salim Abdool Karim, chairperson of the COVID-19 Ministerial Advi-
sory Committee of South Africa.
Healthcare workers should be prioritized to ensure the continuous care of popu-
lations
Many healthcare workers around the world get infected at the workplace and die of COVID-19. According to 
the Centers for Disease Control and Prevention (CDC) COVID data Tracker, more than 400,000 healthcare 
personnel cases occurred in the US since the beginning of the epidemic until end of February 2021 claiming 
1,371 lives [43]. Healthcare workers infected with COVID-19 need to self-isolate, and consequently, many 
healthcare workers with contact to infected healthcare workers need to be quarantined. Thus, entire health-
care services and hospitals, for example the Humboldt Hospital in Berlin [43], were shut down - often for 
weeks - and could not serve the general population. Healthcare workers can also spread COVID-19 to patients 
and residence of long-term facilities. Those individuals often have underlying conditions that increase the 
risk of severe COVID-19 disease. Also, healthcare workers can spread the virus to colleagues at work leading 
to outbreaks amongst staff [44]. Vaccinating healthcare personnel will therefore help to prevent intrahospi-
tal transmission of COVID-19 and to reduce the nosocomial spread of COVID-19 in health services.
Healthcare workers should be immunised first and immediately to protect healthcare capacity and for 
hospitals to maintain safe and operational levels to serve the population continuously, especially in the 
light of emerging SARS-CoV-2 variants that are more infective and lead to increased pressure on healthcare 
systems globally.
In conclusion, COVID-19 pandemic represents a major threat to humankind in many respects, including, 
but not limited, to health and economic related issues. The unprecedented fast development of safe and 
effective vaccines as well as the fast–track emergency use and approval of COVID vaccines by the regulatory 
authorities brought the hope to curtail this threat. To achieve this, vaccination against COVID-19 should be 
seen as a global priority involving all countries. The success against SARS-CoV-2 is dependent of how much 
‘global’ reach will be achieved in a concerted and timely manner. The key factors for success will be based 
on: equity between and within countries on the distribution of vaccines, massive administration and prior-
itization of access based on objective criteria (health care workers, to ensure healthcare is uninterrupted, 
and high-risk groups such as people aged over 65 years and people with chronic conditions such as CVD, to 
reduce severe complications and subsequent pressure on health systems), education of the populations to 
improve trust, and acceptance of COVID-19 vaccine, and, last but not least, ensure the implementation of 
mechanisms for mass production of vaccines at a global level.
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